Table 2 —
Chemical compounds targeting adenosine receptors
| Drug | Pharmacological effects | Clinical effects | References | Stage of development |
|---|---|---|---|---|
| AMP579 | Agonist of A2B receptor | Cardio-protection | PMID: 19730798 | Preclinical |
| Capadenoson (BAY 68-4986) | Partial agonist of A1 receptor | Anti-anginal | PMID: 22370739 NCT00568945 | Phase 1 trials |
| Derenofylline (SLV-320) | Antagonist of A1 receptor | Diuresis | PMID: 21641345 NCT00744341 | Phase 2 trials |
| FK-352 | Antagonist of A1 receptor | Improves intra-dialytic hypotension | PMID: 16395260 | Phase 2 trials |
| GS-9667 (CVT-3619) | Partial agonist of A1 receptor | Anti-insulin sensitizer | PMID: hyperlipidemic, 23427000 PMID: 18494808 | Phase 1 trials |
| MRS-5698 | A3 receptor agonist | Analgesia | PMID: 26111639 | Preclinical |
| Namodenoson (CF-102) | A3 receptor agonist | Antineoplastic | PMID: 23299770 | Phase 2 trials |
| Neladenoson | Partial agonist of A1 receptor | Cardio-protection | PMID: 27624622 | Phase 1 trials |
| PBF-509 | Antagonist of A2A receptor | Antineoplastic | NCT02403193 | Phase 2 trials |
| PBF-680 | Antagonist of A1 receptor | Bronchodilation | NCT03774290 | Phase 2 trials |
| PBF-999 | Antagonist of A2A receptor | Antineoplastic | NCT03786484 | Phase 1 trials |
| Piclidenoson (CF-101) | A3 receptor agonist | Immuno-modulatory | NCT03168256 | Phase 3 trials |
| Preladenant (SCH-420814 or MK-3814) | Antagonist of A2A receptor | Neuroprotection | NCT01227265 | Phase 3 trials |
| Rolofylline (KW-3902) | Antagonist receptor of A1 | Diuresis | PMID: 20925544 | Phase 3 trials |
| Selodenoson (RG-14202) | Partial agonist of A1 receptor | Coronary vasodilator | PMID: 8496817 | Preclinical |
| T-62 | Partial agonist of A1 receptor | Analgesia | NCT00809679 | Phase 2 trials |
| Tecadenoson (CVT-510) | Partial agonist of A1 receptor | AV node blockade | PMID: 15956124 | Phase 3 trials |
| Tonapofylline (BG-9928) | Partial agonist of A1 receptor | Diuresis | PMID: 20926754 | Phase 1 trials |
| Trabodenoson (INO-8875) | Partial agonist of A1 receptor | Reduces intra-ocular pressure | PMID: 27046445 | Phase 2 trials |
| V-81444 | Antagonist of A2A receptor | ADHD Parkinson’s disease | NCT02253745 NCT02764892 | |
| VCP-746 | Partial agonist of A1 and A2B receptors | Cardio-protection | PMID: 27377874 | Preclinical |
| WRC-0571 | Inverse agonist of A1 receptor | Tachycardia | PMID: 8632314 | Preclinical |
ADHD = Attention deficit-hyperactivity disorder; NCT = National ClinicalTrials.gov number; PMID = PubMed identifier.